Chemotherapy Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
278 Pages
January 2024
Region: Global
Fairfield Market Research
ID: 5934346

The global chemotherapy drugs market is projected to witness robust growth, with revenues expected to reach US$170 billion in 2024, surging at a CAGR of 9% to attain a valuation of US$310 billion by the end of 2031. These insights, derived from an extensive market analysis, highlight the significant expansion of the chemotherapy drugs sector, emphasizing key factors driving its growth and potential challenges.

The market encompasses a diverse range of drugs, including alkylating agents, antimetabolites, anti-tumor antibiotics, and others, catering to the increasing number of cancer patients globally.

The surge in chemotherapy drug market revenue is attributed to the focus on improving drug formulations and the development of novel drugs. Manufacturers, equipped with strong research and development teams, are leading the way in innovation, driving overall market growth. Additionally, governments globally are increasing spending on cancer medicines, with the U.S. alone witnessing an increase from US$50 billion in 2017 to US$75 billion in 2021.

Post the pandemic, the International Agency for Research on Cancer reported a notable increase in cancer patients, ranging from 1% in non-small cell lung cancer to a substantial 20% in cervical cancer. The aging population and improved access to healthcare in developed economies are contributing to the exponential growth in the number of patients treated, creating opportunities for the chemotherapy drugs industry.

Why is the Global Chemotherapy Drugs Market Growing?

Increasing Product Launches and Regulatory Approvals

Regulatory agencies, including the United States Food and Drug Administration (FDA), have played a pivotal role in the growth of the chemotherapy drugs market. Recent launches such as the Trilaciclib drug, designed to minimize chemotherapy-induced bone marrow suppression, and the FDA-approved tremelimumab, durvalumab, and platinum-based treatment, are expected to drive high treatment adoption rates.

Can Demand for Chemotherapy Drugs Be Affected in Any Way?

Alternatives and Improved Treatment Options

Scientific discoveries over the past decade have led to the development of specialized medicines targeting malignancies at the molecular level. While traditional chemotherapy drugs have notable side effects, the introduction of alternative treatments like immunotherapy is transforming the cancer treatment landscape. These novel treatments offer better tolerance, lower treatment burden, and improved survival rates for patients.

Country-wise Insights:

Why is the U.S. a Huge Market for Chemotherapy Drug Manufacturers?

Value-Based Payment Models for Cancer Treatment

The U.S. dominated the North American market in 2024. The implementation of value-based payment models, such as the Oncology Care Model, has significantly increased the demand for chemotherapy drugs, with around 5% of U.S. healthcare spending directed towards cancer treatment.

What is the Scenario for Chemotherapy Drugs in the U.K.?

Partnerships between Manufacturers and Government Associations

The U.K., holding 36.6% share of the Europe market in 2024, has seen successful partnerships between pharmaceutical firms and government bodies. Collaborations with NHS England and the National Institute for Health and Care Excellence (NICE) have streamlined the evaluation and support process for novel cancer treatments.

How is Australia Emerging as a Prominent Market for Chemotherapy Drugs?

Improvement in Treatment Outcomes

Australia, commanding 90.8% of the Oceania market in 2024, faces a significant cancer burden. The government's increased investment in cancer treatment, combined with rising cancer prevalence, is propelling Australia as a lucrative market for chemotherapy drug manufacturers.

Competitive Analysis:

Leading manufacturers are focusing on technological advancements and strategic consolidations. Notable examples include GSK's acquisition of Sierra Oncology and regulatory approvals for drugs such as Lenalidomide capsule by Cipla and Lynparza by AstraZeneca India.

In conclusion, the global chemotherapy drugs market is poised for substantial growth, driven by technological advancements, regulatory approvals, and increased government spending on cancer treatment. The industry's ability to adapt to evolving treatment landscapes and embrace innovative solutions will play a crucial role in shaping its future trajectory.

Key Companies Profiled

F. Hoffmann-La Roche Ltd
Celgene Corp
Novartis AG
Bristol-Myers Squibb Co
Johnson & Johnson
Sanofi
Pfizer Inc.
Eli Lilly & Company
ImClone Systems Inc.
GlaxoSmithKline
AstraZeneca
Schering-Plough
Boehringer Ingelheim
Bristol-Myers Squibb
Teva Pharmaceuticals Industries
E. Hoffmann-La Roche Ltd
Merck & Co. Inc.
Chemo Espana SL
Amgen Inc
Bayer AG
Takeda Pharmaceutical Company Limited

Segments of Chemotherapy Drugs Industry Research

By Drug Class:

Alkylating Agents
Antimetabolites
Anti-tumour Antibiotics
Topoisomerase Inhibitors
Mitotic Inhibitors
Plant Alkaloids
Corticosteroids
Miscellaneous Antineoplastic

By Indication:

Cancer
Bone Marrow Diseases
Immune System Disorders
Others

By Route of Administration:

Oral
Parenteral
Others

By Dosage Form:

Capsules/Tablets
Injections
Others

By Distribution Channel:

Retail Pharmacies
Hospital Pharmacies
Ambulatory Surgical Centers

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Chemotherapy Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Chemotherapy Drugs Market Outlook, 2018 - 2031

3.1. Global Chemotherapy Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Alkylating Agents
3.1.1.2. Antimetabolites
3.1.1.3. Anti-tumour Antibiotics
3.1.1.4. Topoisomerase Inhibitors
3.1.1.5. Mitotic Inhibitors
3.1.1.6. Plant Alkaloids
3.1.1.7. Corticosteroids
3.1.1.8. Miscellaneous Antineoplastic
3.2. Global Chemotherapy Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Cancer
3.2.1.2. Bone Marrow Diseases
3.2.1.3. Immune System Disorders
3.2.1.4. Others
3.3. Global Chemotherapy Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Oral
3.3.1.2. Parenteral
3.3.1.3. Others
3.4. Global Chemotherapy Drugs Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. Capsules/Tablets
3.4.1.2. Injections
3.4.1.3. Others
3.5. Global Chemotherapy Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. Retail Pharmacies
3.5.1.2. Hospital Pharmacies
3.5.1.3. Ambulatory Surgical Centers
3.6. Global Chemotherapy Drugs Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.6.1. Key Highlights
3.6.1.1. North America
3.6.1.2. Europe
3.6.1.3. Asia Pacific
3.6.1.4. Latin America
3.6.1.5. Middle East & Africa

4. North America Chemotherapy Drugs Market Outlook, 2018 - 2031

4.1. North America Chemotherapy Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Alkylating Agents
4.1.1.2. Antimetabolites
4.1.1.3. Anti-tumour Antibiotics
4.1.1.4. Topoisomerase Inhibitors
4.1.1.5. Mitotic Inhibitors
4.1.1.6. Plant Alkaloids
4.1.1.7. Corticosteroids
4.1.1.8. Miscellaneous Antineoplastic
4.2. North America Chemotherapy Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Cancer
4.2.1.2. Bone Marrow Diseases
4.2.1.3. Immune System Disorders
4.2.1.4. Others
4.3. North America Chemotherapy Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Oral
4.3.1.2. Parenteral
4.3.1.3. Others
4.4. North America Chemotherapy Drugs Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. Capsules/Tablets
4.4.1.2. Injections
4.4.1.3. Others
4.5. North America Chemotherapy Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. Retail Pharmacies
4.5.1.2. Hospital Pharmacies
4.5.1.3. Ambulatory Surgical Centers
4.5.2. BPS Analysis/Market Attractiveness Analysis
4.6. North America Chemotherapy Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.6.1. Key Highlights
4.6.1.1. U.S. Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
4.6.1.2. U.S. Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
4.6.1.3. U.S. Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
4.6.1.4. U.S. Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
4.6.1.5. U.S. Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.6.1.6. Canada Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
4.6.1.7. Canada Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
4.6.1.8. Canada Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
4.6.1.9. Canada Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
4.6.1.10. Canada Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.6.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Chemotherapy Drugs Market Outlook, 2018 - 2031

5.1. Europe Chemotherapy Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Alkylating Agents
5.1.1.2. Antimetabolites
5.1.1.3. Anti-tumour Antibiotics
5.1.1.4. Topoisomerase Inhibitors
5.1.1.5. Mitotic Inhibitors
5.1.1.6. Plant Alkaloids
5.1.1.7. Corticosteroids
5.1.1.8. Miscellaneous Antineoplastic
5.2. Europe Chemotherapy Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Cancer
5.2.1.2. Bone Marrow Diseases
5.2.1.3. Immune System Disorders
5.2.1.4. Others
5.3. Europe Chemotherapy Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Oral
5.3.1.2. Parenteral
5.3.1.3. Others
5.4. Europe Chemotherapy Drugs Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Capsules/Tablets
5.4.1.2. Injections
5.4.1.3. Others
5.5. Europe Chemotherapy Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Retail Pharmacies
5.5.1.2. Hospital Pharmacies
5.5.1.3. Ambulatory Surgical Centers
5.5.2. BPS Analysis/Market Attractiveness Analysis
5.6. Europe Chemotherapy Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.6.1. Key Highlights
5.6.1.1. Germany Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.2. Germany Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.3. Germany Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.4. Germany Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
5.6.1.5. Germany Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.6. U.K. Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.7. U.K. Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.8. U.K. Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.9. U.K. Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
5.6.1.10. U.K. Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.11. France Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.12. France Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.13. France Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.14. France Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
5.6.1.15. France Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.16. Italy Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.17. Italy Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.18. Italy Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.19. Italy Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
5.6.1.20. Italy Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.21. Turkey Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.22. Turkey Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.23. Turkey Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.24. Turkey Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
5.6.1.25. Turkey Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.26. Russia Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.27. Russia Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.28. Russia Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.29. Russia Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
5.6.1.30. Russia Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.31. Rest of Europe Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.32. Rest of Europe Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
5.6.1.33. Rest of Europe Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.34. Rest of Europe Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
5.6.1.35. Rest of Europe Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Chemotherapy Drugs Market Outlook, 2018 - 2031

6.1. Asia Pacific Chemotherapy Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Alkylating Agents
6.1.1.2. Antimetabolites
6.1.1.3. Anti-tumour Antibiotics
6.1.1.4. Topoisomerase Inhibitors
6.1.1.5. Mitotic Inhibitors
6.1.1.6. Plant Alkaloids
6.1.1.7. Corticosteroids
6.1.1.8. Miscellaneous Antineoplastic
6.2. Asia Pacific Chemotherapy Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Cancer
6.2.1.2. Bone Marrow Diseases
6.2.1.3. Immune System Disorders
6.2.1.4. Others
6.3. Asia Pacific Chemotherapy Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Oral
6.3.1.2. Parenteral
6.3.1.3. Others
6.4. Asia Pacific Chemotherapy Drugs Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Capsules/Tablets
6.4.1.2. Injections
6.4.1.3. Others
6.5. Asia Pacific Chemotherapy Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. Retail Pharmacies
6.5.1.2. Hospital Pharmacies
6.5.1.3. Ambulatory Surgical Centers
6.5.2. BPS Analysis/Market Attractiveness Analysis
6.6. Asia Pacific Chemotherapy Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.6.1. Key Highlights
6.6.1.1. China Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.2. China Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.3. China Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.4. China Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
6.6.1.5. China Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.6. Japan Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.7. Japan Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.8. Japan Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.9. Japan Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
6.6.1.10. Japan Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.11. South Korea Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.12. South Korea Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.13. South Korea Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.14. South Korea Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
6.6.1.15. South Korea Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.16. India Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.17. India Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.18. India Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.19. India Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
6.6.1.20. India Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.21. Southeast Asia Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.22. Southeast Asia Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.23. Southeast Asia Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.24. Southeast Asia Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
6.6.1.25. Southeast Asia Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.26. Rest of Asia Pacific Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.27. Rest of Asia Pacific Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
6.6.1.28. Rest of Asia Pacific Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.29. Rest of Asia Pacific Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
6.6.1.30. Rest of Asia Pacific Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Chemotherapy Drugs Market Outlook, 2018 - 2031

7.1. Latin America Chemotherapy Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Alkylating Agents
7.1.1.2. Antimetabolites
7.1.1.3. Anti-tumour Antibiotics
7.1.1.4. Topoisomerase Inhibitors
7.1.1.5. Mitotic Inhibitors
7.1.1.6. Plant Alkaloids
7.1.1.7. Corticosteroids
7.1.1.8. Miscellaneous Antineoplastic
7.2. Latin America Chemotherapy Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Cancer
7.2.1.2. Bone Marrow Diseases
7.2.1.3. Immune System Disorders
7.2.1.4. Others
7.3. Latin America Chemotherapy Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Oral
7.3.1.2. Parenteral
7.3.1.3. Others
7.4. Latin America Chemotherapy Drugs Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Capsules/Tablets
7.4.1.2. Injections
7.4.1.3. Others
7.5. Latin America Chemotherapy Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Retail Pharmacies
7.5.1.2. Hospital Pharmacies
7.5.1.3. Ambulatory Surgical Centers
7.5.2. BPS Analysis/Market Attractiveness Analysis
7.6. Latin America Chemotherapy Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.6.1. Key Highlights
7.6.1.1. Brazil Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.6.1.2. Brazil Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
7.6.1.3. Brazil Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.6.1.4. Brazil Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
7.6.1.5. Brazil Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.1.6. Mexico Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.6.1.7. Mexico Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
7.6.1.8. Mexico Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.6.1.9. Mexico Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
7.6.1.10. Mexico Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.1.11. Argentina Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.6.1.12. Argentina Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
7.6.1.13. Argentina Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.6.1.14. Argentina Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
7.6.1.15. Argentina Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.1.16. Rest of Latin America Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.6.1.17. Rest of Latin America Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
7.6.1.18. Rest of Latin America Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.6.1.19. Rest of Latin America Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
7.6.1.20. Rest of Latin America Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Chemotherapy Drugs Market Outlook, 2018 - 2031

8.1. Middle East & Africa Chemotherapy Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Alkylating Agents
8.1.1.2. Antimetabolites
8.1.1.3. Anti-tumour Antibiotics
8.1.1.4. Topoisomerase Inhibitors
8.1.1.5. Mitotic Inhibitors
8.1.1.6. Plant Alkaloids
8.1.1.7. Corticosteroids
8.1.1.8. Miscellaneous Antineoplastic
8.2. Middle East & Africa Chemotherapy Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Cancer
8.2.1.2. Bone Marrow Diseases
8.2.1.3. Immune System Disorders
8.2.1.4. Others
8.3. Middle East & Africa Chemotherapy Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Oral
8.3.1.2. Parenteral
8.3.1.3. Others
8.4. Middle East & Africa Chemotherapy Drugs Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Capsules/Tablets
8.4.1.2. Injections
8.4.1.3. Others
8.5. Middle East & Africa Chemotherapy Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. Retail Pharmacies
8.5.1.2. Hospital Pharmacies
8.5.1.3. Ambulatory Surgical Centers
8.5.2. BPS Analysis/Market Attractiveness Analysis
8.6. Middle East & Africa Chemotherapy Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.6.1. Key Highlights
8.6.1.1. GCC Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.6.1.2. GCC Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
8.6.1.3. GCC Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.6.1.4. GCC Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
8.6.1.5. GCC Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.6. South Africa Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.6.1.7. South Africa Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
8.6.1.8. South Africa Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.6.1.9. South Africa Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
8.6.1.10. South Africa Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.11. Egypt Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.6.1.12. Egypt Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
8.6.1.13. Egypt Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.6.1.14. Egypt Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
8.6.1.15. Egypt Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.16. Nigeria Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.6.1.17. Nigeria Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
8.6.1.18. Nigeria Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.6.1.19. Nigeria Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
8.6.1.20. Nigeria Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.21. Rest of Middle East & Africa Chemotherapy Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.6.1.22. Rest of Middle East & Africa Chemotherapy Drugs Market by Indication, Value (US$ Bn), 2018 - 2031
8.6.1.23. Rest of Middle East & Africa Chemotherapy Drugs Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.6.1.24. Rest of Middle East & Africa Chemotherapy Drugs Market by Dosage Form, Value (US$ Bn), 2018 - 2031
8.6.1.25. Rest of Middle East & Africa Chemotherapy Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Drug Class vs Indication Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. F. Hoffmann-La Roche Ltd
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Celgene Corp
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Novartis AG
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Bristol-Myers Squibb Co
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Johnson & Johnson
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Sanofi
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Pfizer Inc.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Eli Lilly & Company
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. ImClone Systems Inc.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. GlaxoSmithKline
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. AstraZeneca
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Schering-Plough
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Boehringer Ingelheim
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
9.4.14. Bristol-Myers Squibb
9.4.14.1. Company Overview
9.4.14.2. Product Portfolio
9.4.14.3. Financial Overview
9.4.14.4. Business Strategies and Development
9.4.15. Teva Pharmaceuticals Industries
9.4.15.1. Company Overview
9.4.15.2. Product Portfolio
9.4.15.3. Financial Overview
9.4.15.4. Business Strategies and Development
9.4.16. E. Hoffmann-La Roche Ltd
9.4.16.1. Company Overview
9.4.16.2. Product Portfolio
9.4.16.3. Financial Overview
9.4.16.4. Business Strategies and Development
9.4.17. Merck & Co. Inc.
9.4.17.1. Company Overview
9.4.17.2. Product Portfolio
9.4.17.3. Financial Overview
9.4.17.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

F. Hoffmann-La Roche Ltd
Celgene Corp
Novartis AG
Bristol-Myers Squibb Co
Johnson & Johnson
Sanofi
Pfizer Inc.
Eli Lilly & Company
ImClone Systems Inc.
GlaxoSmithKline
AstraZeneca
Schering-Plough
Boehringer Ingelheim
Bristol-Myers Squibb
Teva Pharmaceuticals Industries
E. Hoffmann-La Roche Ltd
Merck & Co. Inc.

Methodology

LOADING...